Chimeric jumps 35pc as CHM 1301 demonstrates efficacy in pre-clinical trials. Picture Getty
Health & Biotech
Chimeric Therapeutics (ASX:CHM) continues to make progress in its multiple cell therapy programs.
This morning, shares in the biotech rose 35% after announcing positive pre-clinical data for CHM 1301, its next generation, off-the-shelf CLTX CAR NK cell therapy.
Pre-clinical data showed that CHM 1301 demonstrated highly promising efficacy in in-vitro models.
In ovarian cancer, results show that cell killing was increased up to ~260% as compared to first generation CHM 0201 cells, while in pancreatic cancer, cell killing was increased up to 300% as compared to first generation CHM 0201 cells.
Based on this success, Chimeric said it will be advancing the CHM 1301 program to the next stage of pre-clinical development using its recently developed armoured NK cell platform (CHM 0301).
The positive results of CHM 1301 today also demonstrates the synergies of assets in the Chimeric portfolio.
Today’s results combine nicely with the recently announced efficacy of CHM 1101, Chimeric’s CLTX CAR T cell therapy, and with the efficacy of CHM 02012, Chimeric’s off-the-shelf NK cell platform – to create a whole new next generation of CLTX CAR NK cell therapy.
Jennifer Chow, CEO of Chimeric Therapeutics, said the results today also show the ability for Chimeric to expand into new disease areas.
“Being able to achieve this success through our cost effective, academic collaboration with Dr David Wald at Case Western Reserve University also enables Chimeric to continue to build out a promising next generation pipeline, while focusing resources on our current clinical stage assets,” she added.
Recce Pharmaceuticals (ASX:RCE) was granted Canadian patent claims related to RECCE 327 (R327) and RECCE 529 (R529) drugs.
Most notably, the patents relate to the process for preparation of RECCE anti-infectives, and the use of R327/R529 for the treatment of disease, particularly in treatment of bacterial infections and viral infections.
The patent also addresses and validates RECCE anti-infectives from studies in burn wounds, urinary tract infections, gonorrhoea, influenza, and SARS-CoV2.
This is the first of Recce’s wholly owned patents granted in Canada, with further Patent Cooperation Treaty Country (PCT) submissions already in respective stages of review.
Algorae Pharmaceuticals (ASX:1AI) announced a collaboration with Monash University to undertake pre-clinical studies on the AI-168 drug candidate to treat cardiovascular diseases.
AI-168 is made from cannabinoid and another pharmaceutical drug, with a patent application already filed.
Under the agreement, Monash will employ a suite of state-of-the-art experimental techniques, which are expected to provide an understanding of the mechanism of action of AI-168 across a range of cardiovascular diseases (CVDs).
The pre-clinical efficacy of AI-168 will then be compared to existing classes of drugs used to treat CVDs.
Results are anticipated in multiple deliverable time frames over a period of approximately 12 months.
Health & Biotech
Health & Biotech
Health & Biotech
